Dermatology

This site is intended for healthcare professionals only

Login Register

MD Brand Connect
Webinars
Vaccine Hub
MDTV
Fact Check
Health Dialogues

Medical News & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry
MDTV

This site is intended for healthcare professionals only

Login Register

LoginRegister

Home
Medical news & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at [email protected] Contact no. 011-43720751

Home

Ruchika Sharma

Articles By : Ruchika Sharma

USFDA nod to Alembic Pharma stroke and blood clots drug Dabigatran Etexilate

Written By Ruchika Sharma19 Jun 2024 12:12 PM IST

Vadodara: Alembic Pharmaceuticals Limited has announced that it has received final approval from the US Food & Drug Administration (USFDA)...

Palamur Biosciences Faces USFDA Warning for Multiple GLP Compliance Failures

USFDA issues 15 observations for Jubilant HollisterStier General Partnership Montreal facility

Written By Ruchika Sharma19 Jun 2024 11:15 AM IST

Noida: Jubilant Pharmova Limited has announced that the United States Food and Drug Administration (USFDA) has concluded the audit of the...

CDSCO Panel Flags Ethnic Variability, Seeks More Data from Takeda for Fruquintinib Hard Capsule Approval

Takeda announces Phase 3 topline results for Soticlestat in patients with Dravet Syndrome, Lennox-Gastaut Syndrome

Written By Ruchika Sharma18 Jun 2024 4:14 PM IST

Osaka: Takeda has announced topline data from its SKYLINE and SKYWAY studies. SKYLINE (TAK-935-3001) was a multicenter, randomized, double-blind...

Abhayrab Safe via Authorised Channels, Clarifies Indian Immunologicals Amid Fake Vaccine Alerts

Merck Capvaxive gets USFDA nod for prevention of Invasive Pneumococcal Disease, Pneumococcal Pneumonia in adults

Written By Ruchika Sharma18 Jun 2024 2:04 PM IST

Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the U.S. Food and Drug Administration (FDA) has approved...

USFDA Approves Corcept Therapeutics Ovarian Cancer Drug Lifyorli

USFDA approves Merck Keytruda plus Carboplatin, Paclitaxel for Primary Advanced or Recurrent Endometrial Carcinoma

Written By Ruchika Sharma18 Jun 2024 11:30 AM IST

Rahway: Merck, known as MSD outside of the United States and Canada, has announced the U.S. Food and Drug Administration (FDA) has approved...

USFDA approves Alembic Pharma Icatibant Injection for acute attacks of hereditary angioedema

Written By Ruchika Sharma17 Jun 2024 3:29 PM IST

Icatibant injection is indicated for the treatment of acute attacks of hereditary angioedema in adults 18 years of age and older.

AbbVie Loses India Patent Bid for Cancer Drug Venetoclax, Generics Set to Enter Market

AbbVie, FutureGen ink pact to develop Next-Generation Therapy for Inflammatory Bowel Disease

Written By Ruchika Sharma17 Jun 2024 12:30 PM IST

North Chicago, IlI.: AbbVie and FutureGen Biopharmaceutical (Beijing) Co., Ltd. have announced a license agreement to develop FG-M701, a next...

AstraZenecas Imfinzi Combo Shows Strong Survival Benefit in Liver Cancer Trial

AstraZeneca Imfinzi plus chemotherapy gets USFDA nod for mismatch repair deficient advanced or recurrent endometrial cancer

Written By Ruchika Sharma17 Jun 2024 11:30 AM IST

Cambridge: AstraZeneca has announced that Imfinzi (durvalumab) in combination with carboplatin and paclitaxel followed by Imfinzi monotherapy has...

Biocon Biologics Secures BB+ Rating Upgrade from S&P on Improved Financial Metrics

USFDA issues 3 observations for Biocon Visakhapatnam API facility

Written By Ruchika Sharma16 Jun 2024 11:00 AM IST

Bangalore: Biocon has informed in a BSE filing that the U.S. Food and Drug Administration (USFDA) has concluded...

Takeda signs option agreement with Ascentage Pharma to enter into exclusive global license for Olverembatinib

Written By Ruchika Sharma16 Jun 2024 10:30 AM IST

Japan: Takeda has announced the signing of an option agreement with Ascentage Pharma to enter into an exclusive license agreement for...

CDSCO Panel Clears Bristol Myers Yervoy for Two New Cancer Indications

USFDA approves Bristol Myers Squibb Augtyro for NTRK-Positive Locally Advanced or Metastatic Solid Tumors

Written By Ruchika Sharma15 Jun 2024 4:26 PM IST

Princeton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of...

Sun Pharma Seals Rs 97,500 Crore Organon Acquisition Deal

Sun Pharma, Moebius Medical present positive data from phase 2b trial of MM-II in painful knee osteoarthritis patients at EULAR 2024

Written By Ruchika Sharma15 Jun 2024 12:30 PM IST

Sun Pharma and Moebius Medical, who have been jointly developing MM-II, have announced plans to initiate a Phase 3 clinical program.

Powered By: Hocalwire

X

We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok